Amgen Inc.’s Epogen–Commercializing the First Biotech Blockbuster Drug Harvard Case Solution & Analysis

Amgen Inc.'s Epogen was the first biotech blockbuster drug, which helped in eliminating a condition which comprises of acute tiredness, anemia, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which comprised dialysis patients and persons with cancer undergoing chemotherapy, was estimated to be a $1 billion chance.

After a vital scientific breakthrough, which let the EPO gene to be identified by Amgen, the business employed for quite a few patents to protect its accomplishment. However, much to its surprise, Amgen discovered that EPO had been patented. The holder of the patent, Genetics Institute, needed a royalty-free cross license. Amgen's supervisor needed to decide how best to compete with its competition.

PUBLICATION DATE: December 14, 2005 PRODUCT #: 706454-HCB-ENG

This is just an excerpt. This case is about STRATEGY & EXECUTION

Amgen Inc.’s Epogen–Commercializing the First Biotech Blockbuster Drug Case Solution Other Similar Case Solutions like

Amgen Inc.’s Epogen–Commercializing the First Biotech Blockbuster Drug

Share This